AKRO - Akero Therapeutics (AKRO) Slides After Failed Trial Hit With Class Action Lawsuit – Hagens Berman | Benzinga

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ:AKRO) investors who suffered substantial losses to take action by submitting your losses now.

Class Period: Sep. 13, 2022 – Oct. 9, 2023
Lead Plaintiff Deadline: June 25, 2024
Visit: www.hbsslaw.com/investor-fraud/AKRO
Contact An Attorney Now: AKRO@hbsslaw.com
                                                    844-916-0895

Akero Therapeutics, Inc. (AKRO) Securities Fraud Class Action:

Akero Therapeutics, a biopharmaceutical company developing treatments for liver disease, is facing a securities class action lawsuit over allegations it misled investors about a key clinical trial. The lawsuit centers on the SYMMETRY study, designed to evaluate efruxifermin ("EFX"), Akero's lead drug candidate, for treating nonalcoholic steatohepatitis (NASH), a serious liver condition.

The crux of the complaint lies in Akero's portrayal of the SYMMETRY study's patient population. In June 2019, the FDA issued guidance discouraging the inclusion ...

AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman>Full story available on Benzinga.com